Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jun;39(6):665–669. doi: 10.1111/j.1365-2125.1995.tb05726.x

The axial distribution of nicotine content along hair shaft as an indicator of changes in smoking behaviour: evaluation in a smoking-cessation programme with or without the aid of nicotine chewing gum.

T Uematsu 1, A Mizuno 1, S Nagashima 1, A Oshima 1, M Nakamura 1
PMCID: PMC1365079  PMID: 7654485

Abstract

1. Hair samples were obtained from subjects at the end of a 6 month smoking-cessation programme carried out with (n = 16) or without (n = 10) the aid of nicotine chewing gum. The axial distribution of nicotine along the hair shaft was determined and compared both with the self-report of smoking behavior and with the concentration of carbon monoxide (CO) in expired air measured at 1 month intervals. 2. A gradual decrease in nicotine content along the hair shaft corresponded to the decrease in self-reported number of cigarettes smoked daily in both the nicotine chewing-gum treated and untreated subjects and with the clinical assessment of abstinence. 3. There was reasonable agreement between the CO content of expired air, the self-reported number of cigarettes smoked daily and the axial distribution of nicotine in 22 of 26 subjects. In the other four subjects there was an apparent disagreement between the CO content of expired air and the other parameters. 4. This study showed that, as a routine marker of smoking status, hair analysis may be preferable to repeated CO measurements since only a single sample at the end of an abstinence programme might be sufficient. However, one problem is that nicotine may dissociate slowly from melanin to limit the ability to mark a sudden cessation of smoking. Also, some nicotine in hair might be attributable to nicotine adsorbed to the outside of hair.

Full text

PDF
665

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cepeda-Benito A. Meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. J Consult Clin Psychol. 1993 Oct;61(5):822–830. doi: 10.1037//0022-006x.61.5.822. [DOI] [PubMed] [Google Scholar]
  2. Haley N. J., Hoffmann D. Analysis for nicotine and cotinine in hair to determine cigarette smoker status. Clin Chem. 1985 Oct;31(10):1598–1600. [PubMed] [Google Scholar]
  3. Jarvis M. J., Belcher M., Vesey C., Hutchison D. C. Low cost carbon monoxide monitors in smoking assessment. Thorax. 1986 Nov;41(11):886–887. doi: 10.1136/thx.41.11.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Mao Y., Gibbons L., Wong T. The impact of the decreased prevalence of smoking in Canada. Can J Public Health. 1992 Nov-Dec;83(6):413–416. [PubMed] [Google Scholar]
  5. McGinnis J. M., Foege W. H. Actual causes of death in the United States. JAMA. 1993 Nov 10;270(18):2207–2212. [PubMed] [Google Scholar]
  6. Miyazawa N., Uematsu T. Analysis of ofloxacin in hair as a measure of hair growth and as a time marker for hair analysis. Ther Drug Monit. 1992 Dec;14(6):525–528. doi: 10.1097/00007691-199212000-00015. [DOI] [PubMed] [Google Scholar]
  7. Mizuno A., Uematsu T., Oshima A., Nakamura M., Nakashima M. Analysis of nicotine content of hair for assessing individual cigarette-smoking behavior. Ther Drug Monit. 1993 Apr;15(2):99–104. doi: 10.1097/00007691-199304000-00005. [DOI] [PubMed] [Google Scholar]
  8. Nakano M., Uematsu T., Sato H., Kosuge K., Nishimoto M., Nakashima M. Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol. Eur J Clin Pharmacol. 1994;47(2):195–202. doi: 10.1007/BF00194972. [DOI] [PubMed] [Google Scholar]
  9. Sato H., Uematsu T., Yamada K., Nakashima M. Chlorpromazine in human scalp hair as an index of dosage history: comparison with simultaneously measured haloperidol. Eur J Clin Pharmacol. 1993;44(5):439–444. doi: 10.1007/BF00315540. [DOI] [PubMed] [Google Scholar]
  10. Tang J. L., Law M., Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ. 1994 Jan 1;308(6920):21–26. doi: 10.1136/bmj.308.6920.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Uematsu T., Miyazawa N., Okazaki O., Nakashima M. Possible effect of pigment on the pharmacokinetics of ofloxacin and its excretion in hair. J Pharm Sci. 1992 Jan;81(1):45–48. doi: 10.1002/jps.2600810109. [DOI] [PubMed] [Google Scholar]
  12. Uematsu T., Sato R., Fujimori O., Nakashima M. Human scalp hair as evidence of individual dosage history of haloperidol: a possible linkage of haloperidol excretion into hair with hair pigment. Arch Dermatol Res. 1990;282(2):120–125. doi: 10.1007/BF00493470. [DOI] [PubMed] [Google Scholar]
  13. Uematsu T. Therapeutic drug monitoring in hair samples. Principles and practice. Clin Pharmacokinet. 1993 Aug;25(2):83–87. doi: 10.2165/00003088-199325020-00001. [DOI] [PubMed] [Google Scholar]
  14. Uematsu T. Utilization of hair analysis for therapeutic drug monitoring with a special reference to ofloxacin and to nicotine. Forensic Sci Int. 1993 Dec;63(1-3):261–268. doi: 10.1016/0379-0738(93)90279-j. [DOI] [PubMed] [Google Scholar]
  15. West R. R. Smoking: its influence on survival and cause of death. J R Coll Physicians Lond. 1992 Oct;26(4):357–366. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES